Mouse polyclonal to IGSF8, Host Mouse
- Known as:
- Mouse pab IGSF8, Host Mouse
- Catalog number:
- YF-PA26793
- Product Quantity:
- 50 uL
- Category:
- -
- Supplier:
- Abfron
- Gene target:
- Mouse polyclonal IGSF8 Host
Related genes to: Mouse polyclonal to IGSF8, Host Mouse
- Gene:
- IGSF8 NIH gene
- Name:
- immunoglobulin superfamily member 8
- Previous symbol:
- -
- Synonyms:
- CD81P3, EWI2, PGRL, CD316
- Chromosome:
- 1q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-01-08
- Date modifiied:
- 2016-10-05
Related products to: Mouse polyclonal to IGSF8, Host Mouse
Related articles to: Mouse polyclonal to IGSF8, Host Mouse
- Microplastics and nanoplastics (MNPs), as emerging environmental pollutants, have garnered significant attention from the global scientific community due to their potential threats to human health, particularly their association with the occurrence and development of cancer. The goal of our study is to create a predictive marker for pancreatic ductal adenocarcinoma (PAAD) based on MNPs-related genes, with the purposes of predicting survival outcomes and assessing the tumor immune microenvironment. - Source: PubMed
Publication date: 2026/08/27
Wang GennianCheng HuaZhang YapingGuo XiaohuLi Yumin - To identify plasma protein biomarkers associated with incident non-fatal major adverse cardiovascular events (MACE) in diabetic kidney disease (DKD) patients. - Source: PubMed
Publication date: 2026/08/27
Jiang LiChien ChiehLi TianliZhang HaojunZhao TingtingWu Xiai - Vasculitis is a heterogeneous inflammatory vascular disorder with substantial clinical and molecular diversity. However, hypoxia-associated molecular subtypes in pediatric vasculitis and their differences from adult vasculitis remain poorly defined. - Source: PubMed
Publication date: 2026/06/26
Liu Bin - Immunotherapy has reshaped the oncology landscape by enabling the immune system to recognize and eliminate malignant cells. Although immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have achieved durable responses in several cancers, their therapeutic benefit remains limited to a subset of patients, largely due to immune evasion, tumor heterogeneity, and immunosuppressive features of the tumor microenvironment (TME). This review comprehensively examines the expanding landscape of next-generation immune checkpoints, encompassing both co-inhibitory (lymphocyte activation gene-3 [LAG-3], T cell immunoglobulin and mucin-domain containing-3 [TIM-3], TIGIT, VISTA, and IGSF8) and co-stimulatory (ICOS, OX40, GITR, 4-1BB, CD40, and CD27) pathways that collectively regulate the balance between immune activation and tolerance. We discuss their molecular mechanisms, translational rationale, and emerging clinical evidence, highlighting their potential to reinvigorate antitumor immunity, particularly in ICI-refractory settings. Beyond checkpoint modulation, we explore complementary strategies aimed at remodeling the TME and enhancing immune responsiveness, including targeting immunometabolic pathways (IDO1 and CD73), innate immune sensing (toll-like receptors [TLRs]), cytokine signaling (IL-2), micronutrient immunoregulators (vitamin D), and the gut microbiota. The integration of these approaches into rational combination regimens, guided by predictive features such as T cell infiltration, tumor mutational burden (TMB), and microbiome composition, holds promise for extending the clinical impact of immunotherapy across malignancies. We further advocate for a precision immuno-oncology framework that leverages multiomic profiling, systems biology, and artificial intelligence (AI) to optimize therapeutic selection and mitigate immune-related toxicities. Emerging advances in nanomedicine, synthetic biology, and chronotherapy offer additional opportunities to enhance therapeutic specificity and durability, collectively charting a path from mechanistic insight to clinical translation toward realizing the full curative potential of cancer immunotherapy. Trial Registration: ClinicalTrials.gov identifier: LAG-3 (NCT03470922, NCT04082364, NCT05064059, NCT05352672, NCT02614833, NCT03625323, NCT01968109), TIM-3 (NCT03307785, NCT03680508, NCT02608268, NCT02817633), TIGIT (NCT03563716), VISTA (NCT02671955, NCT02812875), IGSF8 (NCT05669430), CD73 (NCT02503774), B7-H3 (NCT02475213, NCT01391143, NCT02628535, NCT03406949, NCT00089245, NCT01099644, NCT01502917), OX40 (NCT01862900, NCT02315066, NCT02410512, NCT02221960, NCT02528357, NCT02923349, NCT02705482), CD27 (NCT02335918, NCT02924038, NCT02302339, NCT02386111, NCT02543645), 4-1BB (NCT01307267, NCT02444793, NCT01471210, NCT02253992, NCT02554812), CD40 (NCT02588443, NCT03329950), ICOS (NCT02904226, NCT02723955, NCT03251924), GITR (NCT02583165, NCT02132754, NCT02697591, NCT03126110, NCT02740270, NCT02598960, NCT01239134, NCT02628574), IDO1 (NCT02752074, NCT02658890, NCT02077881, NCT01560923, NCT02073123, NCT02327078, NCT02178722), TLRs (NCT02556463, NCT02042781), and IL-2-based therapies (NCT02869295, NCT02983045). - Source: PubMed
Bautista JhommaraEcheverría Carolina EMaldonado-Noboa IvánAdatty-Molina JosethSuárez Urresta SaloméCoral-Riofrio Emily CAraujo-Abad SaloméKyriakidis Nikolaos CLópez-Cortés Andrés - R3HDM4, or R3H domain containing 4, is a gene with uncertain functions but is frequently investigated for its potential cellular roles and associations with various diseases. Kidney renal clear cell carcinoma (KIRC ), a prevalent and aggressive form of kidney cancer, currently lacks effective treatment options. This study aimed to clarify the involvement of R3HDM4 in KIRC pathogenesis. - Source: PubMed
Publication date: 2025/11/19
Sun KaiLi RongXu TingWen SongXu De-ChangWang Ke-Run